PYOTT DAVID E I sold $149K of ALNY
PYOTT DAVID E I sold 495 shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $300.72 ($0.15M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the sale is explicitly under a 10b5-1 plan, it generally carries limited incremental information about near-term fundamentals; any trading impact is likely sentiment-driven and small.
Market read
A disclosed insider sale with a pre-arranged plan—typically not a standalone catalyst for repricing.
What to watch
The disclosure does not state motives or whether other insiders/funds are changing positions; the net signal depends on the broader insider activity trend.
Background
This is an SEC Form 4 insider transaction (director) for Alnylam, reported as an open-market sale executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Alnylam director David Pyott sold 495 shares in an open-market transaction disclosed via SEC Form 4 on June 1 under a 10b5-1 plan.
Likely minimal near-term price impact; watch for broader news flow rather than this disclosure alone.
The filing is an ownership-change disclosure with a stated pre-arranged 10b5-1 plan, reducing interpretability as a reaction to new company-specific information.
Market effects
No direct sector read-through; this is a single-company insider transaction without accompanying operational or clinical updates.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with periods of reduced conviction; traders may still monitor for follow-on filings.
Key entities
- issuerALNY
Alnylam Pharmaceuticals, Inc.; director David E I Pyott sold 495 shares at ~$300.72/share per Form 4.
